Novel entry to the Ergot alkaloids via ring closing metathesis

Katherine L. Lee, Jane Betty Goh and Stephen F. Martin*

Department of Chemistry and Biochemistry, The University of Texas, Austin, TX 78712, USA

Received 22 December 2000; accepted 29 December 2000

Abstract—A novel entry the Ergot alkaloids has been developed. It features a Heck reaction followed by hydride capture to generate the key tricyclic intermediate 12 and a ring closing metathesis reaction to give the tetracyclic ergoline ring system 3.© 2001 Elsevier Science Ltd. All rights reserved.

The development of new and general strategies for the synthesis of biologically important natural and unnatural substances constitutes an area of considerable interest in organic chemistry. In this context, we were attracted some years ago to the potential of using ring closing metathesis (RCM) reactions as key constructions for alkaloid synthesis.1,2 We have recently reported the application of such reactions to the syntheses of manzamine A and FR900482.3,4 As part of an ongoing program in developing the utility of RCM reactions, we were intrigued by the possibility of exploiting such a construction in formulating a novel synthetic approach to the tetracyclic Ergot alkaloids lysergic acid (1) and lysergine (2) via cyclization of a precursor diene such as 4 (R=CO₂Me, Me) (Scheme 1).5 We now report the successful completion of some preliminary studies that establish the underlying viability of a novel entry to the Ergot alkaloids as manifested in the synthesis of the C(8) unsubstituted ergoline derivative 3.

The basic strategy that emerged for preparing 3 was designed to be adaptable so it could be modified in a straightforward fashion for the asymmetric syntheses of the natural Ergot alkaloids, including lysergic acid (1) and lysergine (2). The known dehydrotryptophan 7 was readily prepared by palladium-mediated coupling of the N-tosyl derivative of 4-bromoindole 6 with a protected dehydroalanine in 56% overall yield from 5 (Scheme 2).6,7 N-Methylation of 7 followed by hydrogenation of the dehydroamino acid moiety of 8 with Wilkinson’s catalyst under 100 psi hydrogen proceeded efficiently, albeit slowly, to give the bromotryptophan 9 in about 88% yield. If 10% Pd/C was used as the catalyst, complete hydrogenolysis of the aryl bromide occurred. Although the present route provides 9 as a racemate, it should be possible to modify the synthetic plan to prepare 9 or closely related analogs in an enantiomerically pure form.8

Developing the tactics for converting 9 into the key tricyclic intermediate 12 required considerable experimentation. The first plan was to induce radical cyclization of the bromo acetylene 10 into 12 via a 6-exo-dig closure. Toward this end, reduction of the ester 9 with DIBAL-H furnished an intermediate aldehyde that was transformed directly into the acetylene 10 using 1-diazo-(2-oxopropyl)phosphonate (73% overall yield from 9).9 However, several preliminary attempts to effect radical cyclization of 10 (Bu₃SnH, cat. AIBN, toluene, Δ) afforded only the corresponding debrominated product. Placement of a trimethylsilyl group on terminal acetylenes has been reported to facilitate radical cyclizations and to enhance the exo/endo selectivity,10 but when 11 was treated with (Bu₃SnH in the presence of AIBN, only traces of cyclized product were detected in the reaction mixture.

Keywords: ring closing metathesis; Heck reaction; organometallic; amino acid.
* Corresponding author. E-mail: sfmartin@mail.utexas.edu

Scheme 1.
Scheme 2.

These results did not bode well for preparing 12 by a radical cyclization, so other options were considered, and an intramolecular Heck cyclization emerged as an attractive alternative. The requisite alkene 13 was readily prepared from 9 by sequential DIBAL-H reduction followed by Wittig olefination. However, subjecting 13 to typical Heck conditions [Pd(OAc)$_2$, (o-tol)$_3$P, Bu$_4$NCl, Et$_3$N, MeCN, Δ] afforded the undesired seven-membered ring product 14 in 65% yield. Subsequent examination of models suggested that the 7-endo mode of cyclization allowed more facile attainment of an eclipsed relationship between the aryl carbon–palladium bond, which was formed by oxidative addition, and the reacting carbon–carbon double bond, an arrangement Overman found to favor Heck cyclization. It then occurred to us that one way to disfavor the 7-endo cyclization pathway would be to replace the terminal olefin in 13 with an alkyne moiety, which could not adopt an eclipsed relationship with the aryl carbon–palladium bond. The accessible twisted orientation between the alkyne and the carbon–carbon double bond might then kinetically favor formation of a six-membered ring. After considerable experimentation, we discovered that 10 could be selectively converted into 12 in reasonable yield by a Heck reaction followed by hydride capture. Use of other palladium catalysts, bases, and additives led to the formation of 14 as a significant and inseparable by-product.

With quantities of 12 in hand, the stage was set to examine the key ring closing metathesis. In this context it is noteworthy that there are few examples of RCM reactions involving exocyclic olefins and phenyl substituted alkenes, so success was clearly not assured. Removal of the Boc protecting group from 12 followed by N-alkylation of the amine 15 thus obtained with 4-bromo-1-butene gave 16 in 71% overall yield (Scheme 3).

When 16 was heated with the Grubbs catalyst 18, only small quantities of 17 were formed; however, the RCM of 16 to give 17 using the more reactive Schrock catalyst 19 proceeded in 86% yield. Removal of the tosyl protecting group then delivered the desired ergoline 3 in nearly quantitative yield.

These results further demonstrate the utility of RCM reactions to elaborate the ring systems found in complex alkaloid natural products. Further applications of such processes are under active investigation, and the results of these studies will be reported in due course.
Acknowledgements

We thank the National Institutes of Health, the Robert A. Welch Foundation, Pfizer Inc. and Merck Research Laboratories for their generous support of our research.

References

15. Spectral data for selected compounds: 12, 1H NMR (DMSO-d6, 353 K): δ 7.80–7.87 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 8.1 Hz, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 0.9 Hz, 1H), 7.36–7.30 (comp, 3H), 5.86 (d, J = 2.1 Hz, 1H), 5.04 (d, J = 2.1 Hz, 1H), 4.96–4.91 (m, 1H), 3.09–2.98 (comp, 2H), 2.76 (s, 3H), 2.31 (s, 3H), 1.40 (s, 9H). 13C NMR (DMSO-d6, 353 K): δ 154.6, 144.7, 138.4, 134.4, 132.8, 129.7, 128.8, 127.6, 126.0, 125.5, 120.1, 117.4, 116.8, 112.1, 109.0, 78.7, 55.3, 29.8, 27.9, 24.7, 20.5. 16, 1H NMR (CDCl3): δ 7.76–7.70 (comp, 3H), 7.34–7.16 (comp, 5H), 5.75–5.62 (m, 1H), 5.73 (s, 1H), 5.36 (s, 1H), 5.00–4.89 (comp, 2H), 3.58 (app t, J = 5.8 Hz, 1H), 2.97 (app d, J = 5.8 Hz, 2H), 2.58–2.44 (comp, 2H), 2.31 (s, 3H), 2.22 (s, 3H), 2.19–2.12 (comp, 2H). 13C NMR (CDCl3): δ 144.5, 141.4, 136.8, 135.8, 133.7, 130.4, 129.7, 129.2, 126.7, 125.7, 119.8, 118.9, 117.0, 115.3,
112.3, 64.3, 53.8, 38.4, 31.9, 29.7, 23.4, 21.5; $^{17}$H NMR (CDCl$_3$): $\delta$ 7.74–7.71 (comp, 3H), 7.28–7.17 (comp, 5H), 6.46–6.44 (m, 1H), 3.51 (dd, $J = 15.1$, 5.3 Hz, 1H), 3.09–3.02 (m, 1H), 2.97–2.95 (m, 1H), 2.61–2.51 (comp, 3H), 2.52 (s, 3H), 2.31 (s, 3H), 2.22–2.17 (m, 1H). $^{13}$C NMR (CDCl$_3$): $\delta$ 144.7, 135.6, 133.5, 133.0, 129.8, 129.7, 128.3, 126.7, 125.8, 122.4, 119.8, 117.9, 116.2, 112.1, 62.1, 52.3, 43.7, 26.7, 25.7, 21.5.